MAYO CLINIC LABORATORIES

1-800-533-1710

HGBCE

Hemoglobin Variant, A2 and F Quantitation, Blood

Patient ID	Patient Name		Birth Date	Gender	Age
SA00141471	VALIDATIONTESTING, HGBCE		1970-01-01	F	51
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00141471	SA00141471	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		14 Jan 2021 12:33			

Hb Variant, A2 and F Quantitation,B

Result Name	Value	Unit	Reference Value	Performing Site
Hb A	97.5	%	95.8–98.0	MCR
Hb F	0.2	%	0.0–0.9	MCR
Hb A2	2.3	%	2.0–3.3	MCR

HGBCE Interpretation

[1] MCR

This test utilizes the capillary electrophoresis (CE) method and is useful for rapid quantitation/monitoring of Hb F or previously confirmed abnormal variants after transfusion or other treatments for sickling or other hemoglobinopathy disorders. If variants are detected they will be reported according to CE zone designation but further confirmation or interpretation is not performed. Named zones (zones S, C, E, D, A2, F and A) are non-specific and should not be utilized to infer identification as multiple variants migrate within each designated zone. Recent transfusion (within 4 months) can alter variant percentages and result in the presence of exogenous variants. Some variants do not separate from normal hemoglobin fractions by this method and this is not recommended as a screening test. Small peaks present in Zone 10 or Zone 11 frequently represent a glycated or degraded hemoglobin fraction, respectively. If small peaks are present and quantitated by the instrument, they will be reported in the zone in which they appear. These could represent hemoglobin variants but could also be small degradation peaks or interfering substances.

If identification/classification of hemoglobin variants or further evaluation is desired, please send a new specimen and order a HBEL1/Hemoglobin Electrophoresis Evaluation or THEV1/ Thalassemia and Hemoglobinopathy Evaluation.

Received: 14 Jan 2021 12:49 **Reported:** 14 Jan 2021 13:16

Laboratory Notes

[1] This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292